Table 3.

Adverse Reactions of the 56 Patients with Previous Chemotherapy Resistance Advanced or Metastatic NSCLC

Adverse reactions	Total (N, %)	Grade 1–2 (N, %)	Grade 3–4 (N, %)
Adverse reactions of any grade	50 (89.3)		23 (41.1)
Fatigue	36 (64.3)	31 (55.4)	5 (8.9)
Hypertension	31 (55.4)	22 (39.3)	9 (16.1)
Diarrhea	29 (51.8)	26 (46.4)	3 (5.4)
Nausea and vomiting	25 (44.6)	22 (39.3)	3 (5.4)
Rash	18 (32.1)	16 (28.6)	2 (3.6)
Hand-foot syndrome	15 (26.8)	13 (23.2)	2 (3.6)
Hepatotoxicity	12 (21.4)	8 (14.3)	4 (7.1)
Proteinuria	9 (16.1)	8 (14.3)	1 (1.8)
Pneumonia	7 (12.5)	6 (10.7)	1 (1.8)
Hemorrhage	6 (10.7)	6 (10.7)	0 (0.0)
RCCEP	5 (8.9)	5 (8.9)	0 (0.0)
Myelosuppression	5 (8.9)	4 (7.1)	1 (1.8)